Logo image of DNLI

DENALI THERAPEUTICS INC (DNLI) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:DNLI - US24823R1059 - Common Stock

17.98 USD
+0.61 (+3.51%)
Last: 12/12/2025, 8:25:43 PM
17.7 USD
-0.28 (-1.56%)
After Hours: 12/12/2025, 8:25:43 PM
Fundamental Rating

2

DNLI gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 531 industry peers in the Biotechnology industry. DNLI scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. DNLI does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year DNLI has reported negative net income.
In the past year DNLI has reported a negative cash flow from operations.
DNLI had negative earnings in 4 of the past 5 years.
DNLI had negative operating cash flow in 4 of the past 5 years.
DNLI Yearly Net Income VS EBIT VS OCF VS FCFDNLI Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M -200M 400M -400M

1.2 Ratios

DNLI has a Return On Assets (-41.07%) which is comparable to the rest of the industry.
DNLI's Return On Equity of -46.63% is fine compared to the rest of the industry. DNLI outperforms 67.23% of its industry peers.
Industry RankSector Rank
ROA -41.07%
ROE -46.63%
ROIC N/A
ROA(3y)-21.89%
ROA(5y)-16.39%
ROE(3y)-26.58%
ROE(5y)-20.75%
ROIC(3y)N/A
ROIC(5y)N/A
DNLI Yearly ROA, ROE, ROICDNLI Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -10 -20 -30 -40 -50

1.3 Margins

DNLI does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
DNLI Yearly Profit, Operating, Gross MarginsDNLI Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -200 -400 -600

More info and screens

5

2. Health

2.1 Basic Checks

DNLI does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, DNLI has more shares outstanding
The number of shares outstanding for DNLI has been increased compared to 5 years ago.
DNLI has a worse debt/assets ratio than last year.
DNLI Yearly Shares OutstandingDNLI Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M
DNLI Yearly Total Debt VS Total AssetsDNLI Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B

2.2 Solvency

DNLI has an Altman-Z score of 8.18. This indicates that DNLI is financially healthy and has little risk of bankruptcy at the moment.
DNLI has a better Altman-Z score (8.18) than 78.15% of its industry peers.
A Debt/Equity ratio of 0.01 indicates that DNLI is not too dependend on debt financing.
DNLI has a Debt to Equity ratio of 0.01. This is comparable to the rest of the industry: DNLI outperforms 45.76% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.01
Debt/FCF N/A
Altman-Z 8.18
ROIC/WACCN/A
WACC8.83%
DNLI Yearly LT Debt VS Equity VS FCFDNLI Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500M 1B

2.3 Liquidity

A Current Ratio of 10.27 indicates that DNLI has no problem at all paying its short term obligations.
DNLI has a better Current ratio (10.27) than 81.17% of its industry peers.
A Quick Ratio of 10.27 indicates that DNLI has no problem at all paying its short term obligations.
DNLI has a Quick ratio of 10.27. This is amongst the best in the industry. DNLI outperforms 81.17% of its industry peers.
Industry RankSector Rank
Current Ratio 10.27
Quick Ratio 10.27
DNLI Yearly Current Assets VS Current LiabilitesDNLI Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B

More info and screens

3

3. Growth

3.1 Past

The earnings per share for DNLI have decreased by -1.75% in the last year.
The Revenue for DNLI has decreased by -100.00% in the past year. This is quite bad
EPS 1Y (TTM)-1.75%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-17.46%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

DNLI is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 11.74% yearly.
The Revenue is expected to grow by 133.45% on average over the next years. This is a very strong growth
EPS Next Y-13.54%
EPS Next 2Y-7.32%
EPS Next 3Y-1.08%
EPS Next 5Y11.74%
Revenue Next Year-87.68%
Revenue Next 2Y124.55%
Revenue Next 3Y166.94%
Revenue Next 5Y133.45%

3.3 Evolution

DNLI Yearly Revenue VS EstimatesDNLI Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 500M 1B 1.5B
DNLI Yearly EPS VS EstimatesDNLI Yearly EPS VS EstimatesYearly EPS VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 1 -1 2 -2 -3

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for DNLI. In the last year negative earnings were reported.
Also next year DNLI is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
DNLI Price Earnings VS Forward Price EarningsDNLI Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
DNLI Per share dataDNLI EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 6

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-7.32%
EPS Next 3Y-1.08%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for DNLI!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

DENALI THERAPEUTICS INC

NASDAQ:DNLI (12/12/2025, 8:25:43 PM)

After market: 17.7 -0.28 (-1.56%)

17.98

+0.61 (+3.51%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-06 2025-11-06/amc
Earnings (Next)02-25 2026-02-25/amc
Inst Owners97.59%
Inst Owner Change6.91%
Ins Owners4.55%
Ins Owner Change0.35%
Market Cap2.64B
Revenue(TTM)N/A
Net Income(TTM)-478.94M
Analysts88.33
Price Target32.86 (82.76%)
Short Float %10.68%
Short Ratio8.59
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-4.78%
Min EPS beat(2)-11.43%
Max EPS beat(2)1.88%
EPS beat(4)2
Avg EPS beat(4)2.05%
Min EPS beat(4)-11.43%
Max EPS beat(4)18.24%
EPS beat(8)4
Avg EPS beat(8)2.77%
EPS beat(12)6
Avg EPS beat(12)25.16%
EPS beat(16)7
Avg EPS beat(16)14.02%
Revenue beat(2)0
Avg Revenue beat(2)-100%
Min Revenue beat(2)-100%
Max Revenue beat(2)-100%
Revenue beat(4)0
Avg Revenue beat(4)-100%
Min Revenue beat(4)-100%
Max Revenue beat(4)-100%
Revenue beat(8)0
Avg Revenue beat(8)-98.61%
Revenue beat(12)2
Avg Revenue beat(12)97.93%
Revenue beat(16)4
Avg Revenue beat(16)68.59%
PT rev (1m)0.22%
PT rev (3m)0.22%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0.4%
EPS NY rev (1m)0.97%
EPS NY rev (3m)1.91%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)1400.17%
Revenue NY rev (3m)-88.9%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 2.57
P/tB 2.57
EV/EBITDA N/A
EPS(TTM)-2.91
EYN/A
EPS(NY)-3.08
Fwd EYN/A
FCF(TTM)-2.51
FCFYN/A
OCF(TTM)-2.38
OCFYN/A
SpS0
BVpS7
TBVpS7
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -41.07%
ROE -46.63%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-21.89%
ROA(5y)-16.39%
ROE(3y)-26.58%
ROE(5y)-20.75%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score1
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.01
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 152.73%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 10.27
Quick Ratio 10.27
Altman-Z 8.18
F-Score1
WACC8.83%
ROIC/WACCN/A
Cap/Depr(3y)141.82%
Cap/Depr(5y)112.16%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-1.75%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-17.46%
EPS Next Y-13.54%
EPS Next 2Y-7.32%
EPS Next 3Y-1.08%
EPS Next 5Y11.74%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next Year-87.68%
Revenue Next 2Y124.55%
Revenue Next 3Y166.94%
Revenue Next 5Y133.45%
EBIT growth 1Y-7.75%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-4.91%
EBIT Next 3Y2.29%
EBIT Next 5Y17.92%
FCF growth 1Y-14.63%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-15.93%
OCF growth 3YN/A
OCF growth 5YN/A

DENALI THERAPEUTICS INC / DNLI FAQ

What is the ChartMill fundamental rating of DENALI THERAPEUTICS INC (DNLI) stock?

ChartMill assigns a fundamental rating of 2 / 10 to DNLI.


What is the valuation status for DNLI stock?

ChartMill assigns a valuation rating of 0 / 10 to DENALI THERAPEUTICS INC (DNLI). This can be considered as Overvalued.


How profitable is DENALI THERAPEUTICS INC (DNLI) stock?

DENALI THERAPEUTICS INC (DNLI) has a profitability rating of 1 / 10.


Can you provide the financial health for DNLI stock?

The financial health rating of DENALI THERAPEUTICS INC (DNLI) is 5 / 10.


What is the expected EPS growth for DENALI THERAPEUTICS INC (DNLI) stock?

The Earnings per Share (EPS) of DENALI THERAPEUTICS INC (DNLI) is expected to decline by -13.54% in the next year.